Unicycive Therapeutics, Inc. (UNCY): Shareholders' Equity
$30.20M
As of 2025-12-31
$53.27M
As of 2026-06-30
| Period ended | Shareholders' Equity | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $30.20M | +306.4% | 2026-03-30, Balance as of period end |
| 2024-12-31 | $7.43M | n/m | 2026-03-30, Balance as of period end |
| 2023-12-31 | -$3.81M | n/m | 2025-03-31, Balance as of period end |
| 2022-12-31 | -$466.0K | n/m | 2024-03-28, Balance as of period end |
| 2021-12-31 | $16.48M | n/m | 2023-03-31, Balance as of period end |
| 2020-12-31 | -$2.67M | n/a | 2022-03-31, Balance as of period end |
Shareholders' Equity at similar companies
| Company | Year ended | Shareholders' Equity | Change YoY |
|---|---|---|---|
| Unicycive Therapeutics, Inc. (UNCY) | 2025-12-31 | $30.20M | +306.4% |
| Vistagen Therapeutics, Inc. (VTGN) | 2026-03-31 | $35.52M | -49.5% |
| Coya Therapeutics, Inc. (COYA) | 2025-12-31 | $43.03M | +8.7% |
| NextCure, Inc. (NXTC) | 2025-12-31 | $34.94M | -46.6% |
| Opus Genetics, Inc. (IRD) | 2025-12-31 | $15.35M | +128.3% |
| Akari Therapeutics Plc (AKTX) | 2025-12-31 | $28.33M | +27.4% |
| Atossa Therapeutics, Inc. (ATOS) | 2025-12-31 | $39.35M | -44.9% |
| Verrica Pharmaceuticals Inc. (VRCA) | 2025-12-31 | $24.74M | n/m |
| Actinium Pharmaceuticals, Inc. (ATNM) | 2025-12-31 | $7.83M | -76.1% |
Compare UNCY, VTGN, COYA, NXTC side by side · Screen every company in Pharmaceutical Preparations ↗